港股异动 | 来凯医药-B(02105)涨超12% 核心管线具备多项催化剂 “增肌减脂”管线研发加速推进

智通财经06-25

智通财经APP获悉，来凯医药-B(02105)最高涨超12%，截至发稿，涨10.9%，报5.9港元，成交额432.4万港元。消息面上，来凯医药上月宣布，继获美国FDA新药临床试验(IND)批准后，其自主研发的LAE102(ActRIIA单克隆抗体)已获得国家药监局药品审评中心的IND批准，用于治疗肥胖症患者。公司正加速I期临床试验准备工作。据悉，近年来，以司美格鲁肽为首的GLP-1靶点减肥药席卷全...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446852619?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-25 11:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446852619","market":"hk","top_or_hot":-1,"title":"港股异动 | 来凯医药-B(02105)涨超12% 核心管线具备多项催化剂 “增肌减脂”管线研发加速推进","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，来凯医药-B(02105)最高涨超12%，截至发稿，涨10.9%，报5.9港元，成交额432.4万港元。消息面上，来凯医药上月宣布，继获美国FDA新药临床试验(IND)批准后，其自主研发的LAE102(ActRIIA单克隆抗体)已获得国家药监局药品审评中心的IND批准，用于治疗肥胖症患者。公司正加速I期临床试验准备工作。据悉，近年来，以司美格鲁肽为首的GLP-1靶点减肥药席卷全...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1139960.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 来凯医药-B(02105)涨超12% 核心管线具备多项催化剂 “增肌减脂”管线研发加速推进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 来凯医药-B(02105)涨超12% 核心管线具备多项催化剂 “增肌减脂”管线研发加速推进\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-25 11:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1139960.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，来凯医药-B(02105)最高涨超12%，截至发稿，涨10.9%，报5.9港元，成交额432.4万港元。消息面上，来凯医药上月宣布，继获美国FDA新药临床试验(IND)批准后，其自主研发的LAE102(ActRIIA单克隆抗体)已获得国家药监局药品审评中心的IND批准，用于治疗肥胖症患者。公司正加速I期临床试验准备工作。据悉，近年来，以司美格鲁肽为首的GLP-1靶点减肥药席卷全...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1139960.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSTECH","symbol_name":"恒生科技指数","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1139960.html","article_id":"2446852619","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446852619","pubTimestamp":1719286197,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，来凯医药-B最高涨超12%，截至发稿，涨10.9%，报5.9港元，成交额432.4万港元。消息面上，来凯医药上月宣布，继获美国FDA新药临床试验批准后，其自主研发的LAE102已获得国家药监局药品审评中心的IND批准，用于治疗肥胖症患者。据悉，近年来，以司美格鲁肽为首的GLP-1靶点减肥药席卷全市场。2024年，减肥药概念热度依旧高涨。此外，太平洋证券指出，2024年公司核心管线具有多项催化剂。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HSTECH":"恒生科技指数","BK1161":"生物科技","YANG":"三倍做空富时中国ETF-Direxion","07226":"XL二南方恒科","02105":"来凯医药-B","HSCEI":"国企指数"},"translate_title":"Hong Kong stocks changed, Laikai Medicine-B (02105) rose by more than 12%. The core pipeline has multiple catalysts and the research and development of the \"muscle-increasing and fat-reducing\" pipeline is accelerating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1,"07226":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"智通财经APP获悉，来凯医药-B(02105)最高涨超12%，截至发稿，涨10.9%，报5.9港元，成交额432.4万港元。消息面上，来凯医药上月宣布，继获美国FDA新药临床试验(IND)批准后，其自主研发的LAE102(ActRIIA单克隆抗体)已获得国家药监局药品审评中心的IND批准，用于治疗肥胖症患者。公司正加速I期临床试验准备工作。据悉，近年来，以司美格鲁肽为首的GLP-1靶点减肥药席卷全市场。2024年，减肥药概念热度依旧高涨。诺和诺德和礼来业绩持续大涨也正是得益于市场对减肥药的需求激增。此外，太平洋证券指出，2024年公司核心管线具有多项催化剂。来凯医药此前公布，LAE 002 (afuresertib，一种口服AKT抑制剂)联合氟维司群针对PIK3CA/ AKT1/ PTEN改变的HR+/ HER2-局部晚期或转移性乳腺癌(LA/mBC)在中国展开的III期临床试验AFFIRM-205，已启动患者招募，并完成首例患者入组。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446852619"}